JOHN W. KOZARICH - 24 Apr 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Director
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: John W. Kozarich
Issuer symbol: LGND
Transactions as of: 24 Apr 2024
Net transactions value: +$113,840
Form type: 4
Filing time: 26 Apr 2024, 18:35:31 UTC
Previous filing: 13 Jun 2023
Next filing: 18 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Options Exercise	$113,840	+2,893	+7.3%	$39.35	42,523	24 Apr 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,893	-100%	$0.000000^*	0	24 Apr 2024	Common Stock	2,893	$39.35	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.